Arcellx (ACLX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 28, 2025, to be held virtually for stockholders of record as of April 4, 2025.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report or Form 10-K, are available online, with options to request paper or email copies.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2028 annual meeting: Rami Elghandour, David Lubner, and Kristin Myers.
Advisory vote to approve compensation of named executive officers as disclosed in the 2024 Summary Compensation Table.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board of directors and corporate governance
Board recommends voting for all director nominees and for the executive compensation and auditor ratification proposals.
Latest events from Arcellx
- Net loss increased to $228.9M in 2025; Gilead acquisition and FDA BLA review underway.ACLX
Q4 202526 Feb 2026 - 97% response rate, deep MRD negativity, and no delayed neurotoxicity in RRMM.ACLX
Status Update11 Jan 2026 - Anito-cel demonstrates best-in-class efficacy and safety, targeting a 2026 launch with strong growth prospects.ACLX
TD Cowen 45th Annual Healthcare Conference23 Dec 2025 - Anito-cel delivers 96% response, 74% CR, and no delayed neurotoxicity in advanced myeloma.ACLX
Status Update19 Dec 2025 - Key votes on directors, executive pay, and auditor, with emphasis on diversity and governance.ACLX
Proxy Filing2 Dec 2025 - Anito-cel demonstrates robust efficacy, unique safety, and readiness for a 2026 launch.ACLX
TD Cowen's 6th Annual Oncology Innovation Summit24 Nov 2025 - Anito-cel combines best-in-class efficacy, safety, and operational scalability for broad myeloma adoption.ACLX
Status Update14 Nov 2025 - Net loss rose to $170.8 million as collaboration revenue fell and G&A expenses increased.ACLX
Q3 20255 Nov 2025 - Anito-cel shows robust efficacy and safety, targeting a 2026 launch with broad market potential.ACLX
Morgan Stanley 23rd Annual Global Healthcare Conference21 Oct 2025